EHA 2022 | Maintenance therapy in AML
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives his thoughts on the use of maintenance therapy in patients with acute myeloid leukemia (AML). Dr Kadia notes the use of azacitidine (CC-486) as maintenance therapy in patients with AML, as well as a number of ongoing trials assessing other agents for maintenance therapy in these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting: AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi-Aventis, Servier
Grant/Research Support: AbbVie, Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Celgene, Cellenkos, Cyclacel, Delta-Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron
Speaker’s Bureau: Cure, Hikma
Honoraria: Genzyme
